ImmunoGen Inc (IMGN)

[vinmantoo]

Today's news ought to be good news, but the Street has apparently taken it the other way. The $34 million is viewed as too small, without recognizing that more will be coming with FDA approval of the Mirasol data, probably early next year. Of course, then come the royalties on sales.

I was reading what Dew Diligence wrote on the BioTech values board and his comment makes sense. This deal is good news for IMGN investors but likely those who came on board late were looking for a quick buck due to a buyout offer. The negative reaction to the deal with Takeda must be that it lessens the possibility of a buyout, at least in the near term as IMGN is making deals to expand Elahere sales. The drop today doesn't bother me as IMGN is bouncing back before the close today. It wouldn't surprise me to see IMGN get it all back tomorrow as investors look at this drop as a buying opportunity.